Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 5;23(12):85.
doi: 10.1007/s11926-021-01038-2.

Epidemiology of Antiphospholipid Syndrome in the General Population

Jesse Y Dabit #  1 , Maria O Valenzuela-Almada #  1 , Sebastian Vallejo-Ramos  1 , Alí Duarte-García  2   3
Affiliations
Review

Epidemiology of Antiphospholipid Syndrome in the General Population

Jesse Y Dabit et al. Curr Rheumatol Rep. .

Abstract

Purpose of review: The epidemiology of antiphospholipid syndrome (APS) is poorly understood. Here, we review the current understanding of the epidemiology of antiphospholipid syndrome in the general population and the frequency of antiphospholipid antibodies in the general population in patients with obstetric morbidity, arterial events, and venous thromboembolism.

Recent findings: There have been few population-based studies that estimated the prevalence and incidence of APS. The estimated incidence and prevalence among most these studies ranged between 1 and 2 cases per 100,000 and 40 and 50 cases per 100,000 respectively. The prevalence of antiphospholipid antibodies in patients with obstetric morbidity was 6-9%, while in arterial events and venous thromboembolism is 9-10%. However, this data remains limited. Mortality of patients with APS is 50-80% higher than the general population. The epidemiology of APS has been difficult to elucidate. Population-based studies patients with diverse age, racial, and ethnic backgrounds are needed.

Keywords: Antiphospholipid syndrome; Epidemiology.

PubMed Disclaimer

Conflict of interest statement

Jesse Dabit declares that he has no conflict of interest.

Maria O. Valenzuela- Almada declares that she has no conflict of interest.

Sebastian Vallejo-Ramos declares that he has no conflict of interest.

Alí Duarte-García declares that he has no conflict of interest.

References

    1. Corban MT, Duarte-Garcia A, McBane RD, Matteson EL, Lerman LO, Lerman A. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69(18):2317–2330. doi: 10.1016/j.jacc.2017.02.058. - DOI - PubMed
    1. Bobba RS, Johnson SR, Davis AM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value? J Rheumatol. 2007;34(7):1522–1527. - PubMed
    1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4(2):295–306. doi: 10.1111/j.1538-7836.2006.01753.x. - DOI - PubMed
    1. Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548–560. doi: 10.1038/nrrheum.2017.124. - DOI - PubMed
    1. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354–364. doi: 10.1160/TH13-06-0509. - DOI - PubMed

Substances